Brokers Set Expectations for GLSI Q1 Earnings

Greenwich LifeSciences, Inc. (NASDAQ:GLSI) – Research analysts at HC Wainwright issued their Q1 2027 earnings per share (EPS) estimates for Greenwich LifeSciences in a report released on Tuesday, July 21st. HC Wainwright analyst Y. Chen expects that the company will post earnings of ($0.30) per share for the quarter. HC Wainwright has a “Buy” rating and a $69.00 price objective on the stock. The consensus estimate for Greenwich LifeSciences’ current full-year earnings is ($1.35) per share. HC Wainwright also issued estimates for Greenwich LifeSciences’ Q2 2027 earnings at ($0.29) EPS, Q3 2027 earnings at ($0.29) EPS and Q4 2027 earnings at ($0.29) EPS.

Other equities research analysts have also recently issued reports about the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Greenwich LifeSciences in a research note on Friday, May 15th. Wall Street Zen cut shares of Greenwich LifeSciences from a “hold” rating to a “sell” rating in a research report on Saturday, June 6th. Two investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Hold” and an average price target of $57.00.

Greenwich LifeSciences Stock Down 9.4%

NASDAQ:GLSI opened at $13.27 on Wednesday. The company has a market capitalization of $194.80 million, a PE ratio of -8.45 and a beta of 1.40. Greenwich LifeSciences has a 52-week low of $7.78 and a 52-week high of $34.10. The stock has a fifty day simple moving average of $22.69 and a 200-day simple moving average of $24.50.

Institutional Trading of Greenwich LifeSciences

Institutional investors and hedge funds have recently made changes to their positions in the stock. Vanguard Group Inc. boosted its stake in shares of Greenwich LifeSciences by 4.9% during the third quarter. Vanguard Group Inc. now owns 282,181 shares of the company’s stock valued at $2,808,000 after acquiring an additional 13,179 shares during the last quarter. Geode Capital Management LLC lifted its holdings in Greenwich LifeSciences by 6.7% in the 4th quarter. Geode Capital Management LLC now owns 151,684 shares of the company’s stock valued at $3,187,000 after purchasing an additional 9,568 shares in the last quarter. State Street Corp lifted its holdings in Greenwich LifeSciences by 19.3% in the 4th quarter. State Street Corp now owns 97,777 shares of the company’s stock valued at $2,054,000 after purchasing an additional 15,831 shares in the last quarter. Marshall Wace LLP acquired a new stake in shares of Greenwich LifeSciences during the 2nd quarter worth about $509,000. Finally, Bank of New York Mellon Corp grew its holdings in shares of Greenwich LifeSciences by 235.5% during the first quarter. Bank of New York Mellon Corp now owns 46,523 shares of the company’s stock worth $1,117,000 after buying an additional 32,657 shares in the last quarter. 4.16% of the stock is currently owned by hedge funds and other institutional investors.

About Greenwich LifeSciences

Greenwich LifeSciences, Inc (NASDAQ: GLSI) is a clinical-stage biotechnology company focused on the development of novel immune modulators for the treatment of cancer and autoimmune diseases. The company’s product pipeline includes candidates engineered to activate or regulate key components of the innate and adaptive immune systems, with programs advancing through preclinical and early-stage clinical studies.

Headquartered in Greenwich, Connecticut, Greenwich LifeSciences conducts its research and development activities primarily in the United States.